Cotsiranib clinical trials
Also written STP705.
How each study uses cotsiranib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cotsiranib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Sirnaomics (10)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test cotsiranib.
- Jul 2027STP705 Injection for Submental Fat ReductionPhase 2 · Sirnaomics
Studies
Open first, then newest update. How each study uses cotsiranib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- STP705 Injection for Submental Fat ReductionRecruitingPhase 2SirnaomicsNCT07677683Written as STP705
- Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCCTerminatedPhase 1/2SirnaomicsNCT05421013Written as STP705
- Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell CarcinomaCompletedPhase 2SirnaomicsNCT04669808Written as STP705
- Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic ScarsWithdrawnPhase 1/2SirnaomicsNCT05196373Written as STP705
- A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid RecurrenceCompletedPhase 2SirnaomicsNCT04844840Written as STP705
- Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard TherapyCompletedPhase 1SirnaomicsNCT04676633Written as STP705
- A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing AbdominoplastyCompletedPhase 1SirnaomicsNCT05422378Written as STP705
- A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCCCompletedPhase 2SirnaomicsNCT04844983Written as STP705
- Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCCCompletedPhase 1/2SirnaomicsNCT04293679Written as STP705
- A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic ScarCompletedPhase 1/2SirnaomicsNCT02956317Written as STP705
Codes
What other systems call cotsiranib · ClinicalTrials.gg INT018719
- UNII (FDA) ZT3VR2T6GYCOTSIRANIBOne source FDA
- NCI Thesaurus C175941CotsiranibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZT3VR2T6GY | COTSIRANIB | One source FDA |
| NCI Thesaurus | C175941 | Cotsiranib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.